Australasian Polymyalgia Rheumatica and Large Vessel Vasculitis Interest Group (APLIG)

 
The Australasian Polymyalgia Rheumatica and Large Vessel Vasculitis Interest Group (APLIG) was created to formalise an existing network of clinicians and researchers throughout Australia and Asia-Pacific undertaking clinical research in PMR and LVV. This special interest Group (SIG) is intended to facilitate the involvement of other like-minded ARA members, particularly early career researchers, and encourage future collaborative efforts.
 
Mission and Objectives
APLIG recognises that the generation of high-quality evidence which supports practice change and quality improvement is integral to enhancing the care provided to all PMR and/or LVV patients in Australasia and around the world.
 
The following list outlines APLIG’s key objectives at the time of its inception:
  • To establish a national research network that enables multi-site clinical research studies in PMR and/or LVV;
  • To develop best practice guidelines for the management of PMR and LVV;
  • To engage patient-facing organisations to improve public awareness about PMR and LVV, and advocate for patients living with these chronic rheumatic diseases;
  • To facilitate educational opportunities within the ARA and the broader medical community in the areas of PMR and LVV.
New members are warmly welcomed; interested parties should contact the APLIG secretary, Dr Claire Owen, via e-mail (claire.owen@austin.org.au).